ONEOK's $4.4B Brazos Acquisition and $9B Apollo Investment Reshape Balance Sheet and Growth Outlook

What happened

ONEOK completed a $4.425 billion acquisition of Brazos Midstream and secured a $9 billion equity investment from Apollo, which together improved its credit rating to BBB+ and reduced leverage. The company raised 2026 EBITDA guidance three times, now projecting $8.55 billion, up from earlier ranges, citing strong commodity prices and operational execution. The DeepValue report previously rated ONEOK a potential buy at $77.74 with a 5.5% dividend yield and base case of $85, but flagged high leverage (4.79x net debt/EBITDA) and near-breakeven free cash flow after capex and dividends. While the new deals address the balance sheet and growth concerns, they introduce integration and execution risks, and the $9 billion equity injection likely dilutes existing shareholders significantly. The article's tone is optimistic, so independent verification of synergies and the sustainability of the EBITDA target is essential.

Implication

Short-term, the equity injection and credit upgrade should reduce financial risk and potentially support the stock price, as the market appreciates lower leverage and enhanced cash flow visibility. However, the $9 billion from Apollo likely results in significant share dilution, so per-share metrics may not improve as much as headline EBITDA growth suggests. The Brazos acquisition adds assets in a growing basin, but integration risk and the price paid need to be evaluated against expected synergies and cash flow accretion. Investors should track whether the $8.55 billion EBITDA guidance is achieved through organic growth and synergies rather than commodity price spikes, and whether free cash flow turns positive enough to fund dividends and capex without new debt. Given the prior report's base case of $85 and upside to $95, the improved fundamentals could push fair value higher, but the increased share count may cap per-share upside, so a cautious but positive stance is warranted with entry below $85.

Thesis delta

The new deals accelerate deleveraging and add growth, potentially raising EBITDA beyond prior expectations. However, equity dilution from Apollo and integration risk moderate per-share benefits. The thesis shifts from 'income with modest growth' to 'growth with improved balance sheet but higher execution risk'.